Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N.V., has launched generic sofosbuvir 400 mg tablets under the brand name MyHep in India. The product is used for the treatment of chronic hepatitis C,which is a long-lasting infection with the hepatitis C virus. Chronic hepatitis C is a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.
In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead granting Mylan the non-exclusive rights to manufacture and distribute generic sofosbuvir in 91 developing countries, including India.
The launch of Mylan's MyHep offers hope to millions of hepatitis C patients in India who are in need of a high quality, effective and affordable treatment option. MyHep is an important invention to Mylan's growing commercial business in India. The company also offers four additional unique and innovative segments - critical care, HIV care, women's care and oncology.
Subscribe to PharmaTutor News Alerts by Email >>
